Biologics in dermatology

Question 1

Belimumab MOA?

Answer 1

Belimumab is a fully humanized monoclonal antibody directed against soluble B-lymphocyte stimulator. It is used in the treatment of systemic lupus erythematosus.

Question 2

Adalimumab MOA?

Answer 2

Anti TNF-a

Question 3

Mycophenolate mofetil MOA?

Answer 3

Mycophenolate mofetil prevents T-cell and B-cell proliferation by reversible inhibition of inosine monophosphate dehydrogenase. It is effective in managing cutaneous sarcoidosis and neurosarcoidosis.

Question 4

Lebrikizumab?

Answer 4

EBGLYSS™ is an interleukin-13 antagonist indicated for the treatment of adults and pediatric patients 12 years of age (recent approval) and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when
those therapies are not advisable. EBGLYSS can be used +/- topical corticosteroids.

Question 5

Lebrikizumab dosing & side effects?

Answer 5

Initial dose of 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dosage is 250 mg every 4 weeks.
* Hypersensitivity
* Conjunctivitis and Keratitis
* Helminth infections
* Live vaccines should be avoided